PE20090103A1 - DERIVADOS DE PIRIDINA Y PIRIMIDINA COMO ANTAGONISTAS DEL mGluR2 - Google Patents
DERIVADOS DE PIRIDINA Y PIRIMIDINA COMO ANTAGONISTAS DEL mGluR2Info
- Publication number
- PE20090103A1 PE20090103A1 PE2008000591A PE2008000591A PE20090103A1 PE 20090103 A1 PE20090103 A1 PE 20090103A1 PE 2008000591 A PE2008000591 A PE 2008000591A PE 2008000591 A PE2008000591 A PE 2008000591A PE 20090103 A1 PE20090103 A1 PE 20090103A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- trifluoromethyl
- antagonists
- mglur2
- pyridine
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I, EN EL QUE UNO DE ENTRE X O Y ES N Y EL OTRO ES CH, O AMBOS X E Y SON N; Q ES S, O, -CH=N- O -N=CH-; A ES ARILO O UN HETEROARILO DE 5 A 6 MIEMBROS; B ES ARILO O UN HETEROARILO DE 5 A 6 MIEMBROS, OPCIONALMENTE SUSTITUIDOS POR HALO, ALQUILO(C1-C6), -(SO2)-OH, NRaRb, ENTRE OTROS; DONDE Ra Y Rb SON H, ALQUILO(C1-C6) O -(CO)-ALQUILO(C1-C6); R1 ES H, HALOGENO O ALQUILO(C1-C6); R2 ES CIANO, ALCOXI(C1-C6), HALOALQUILO(C1-C6), NRjRk, ENTRE OTROS; DONDE Rj Y Rk SON H, ARILO, CICLOALQUILO(C3-C8), ENTRE OTROS. SON SELECCIONADOS 5-{3-[4-(5-CLORO-TIOFEN-2-IL)-6-TRIFLUOROMETIL-PIRIMIDIN-2-IL]-FENIL}-PIRIDIN-2-ILAMINA, 4-[4-TRIFLUOROMETIL-6-(6-TRIFLUOROMETIL-PIRIDIN-3-IL)-PIRIMIDIN-2-IL]-[2,3']BIPIRIDINIL-6'-ILAMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION Y COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE GLUTAMATO METABOTROPICO, UTILES EN LA PREVENCION Y/O TRATAMIENTO DE TRASTORNOS DEL SNC, TALES COMO PSICOSIS, ALZHEIMER, PERDIDA DE MEMORIA, GLIOMA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07105429 | 2007-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090103A1 true PE20090103A1 (es) | 2009-02-13 |
Family
ID=39457413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000591A PE20090103A1 (es) | 2007-04-02 | 2008-04-01 | DERIVADOS DE PIRIDINA Y PIRIMIDINA COMO ANTAGONISTAS DEL mGluR2 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8012986B2 (es) |
| EP (1) | EP2142527B1 (es) |
| JP (1) | JP5303544B2 (es) |
| KR (1) | KR101143152B1 (es) |
| CN (1) | CN101641346B (es) |
| AR (1) | AR065891A1 (es) |
| AT (1) | ATE493400T1 (es) |
| AU (1) | AU2008233956B2 (es) |
| BR (1) | BRPI0809971A2 (es) |
| CA (1) | CA2681733A1 (es) |
| CL (1) | CL2008000936A1 (es) |
| DE (1) | DE602008004236D1 (es) |
| IL (1) | IL200780A (es) |
| MX (1) | MX2009010505A (es) |
| PE (1) | PE20090103A1 (es) |
| TW (1) | TW200845999A (es) |
| WO (1) | WO2008119689A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009203693B2 (en) * | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
| EP2604602A4 (en) | 2010-08-11 | 2013-12-18 | Taisho Pharmaceutical Co Ltd | HETEROARYLPYRAZOLDERIVAT |
| JP2014062047A (ja) * | 2011-01-21 | 2014-04-10 | Taisho Pharmaceutical Co Ltd | ピラゾール誘導体 |
| AU2012311458B2 (en) * | 2011-09-21 | 2016-02-04 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mTOR inhibitors |
| CA2864085C (en) * | 2012-02-08 | 2021-11-23 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| JP2015534993A (ja) | 2012-10-23 | 2015-12-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａ | 自閉症性障害の処置のためのｍＧｌｕ２／３アンタゴニスト |
| WO2015162076A2 (en) | 2014-04-23 | 2015-10-29 | F. Hoffmann-La Roche Ag | Mglu2/3 antagonists for the treatment of intellectual disabilities |
| US9969726B2 (en) * | 2014-06-10 | 2018-05-15 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof |
| MA45857A (fr) | 2016-07-29 | 2021-05-19 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
| JP2019523279A (ja) | 2016-07-29 | 2019-08-22 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 化合物および組成物ならびにそれらの使用 |
| CA3070993A1 (en) | 2017-08-02 | 2019-02-07 | Sunovion Pharmaceuticals Inc. | Isochroman compounds and uses thereof |
| US20210269414A1 (en) * | 2018-06-22 | 2021-09-02 | Bayer Aktiengesellschaft | Process for preparing tricyclic compounds |
| JP2022525169A (ja) | 2019-03-14 | 2022-05-11 | サノビオン ファーマシューティカルズ インク | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA74419C2 (uk) * | 2001-02-21 | 2005-12-15 | Ен Пі Ес Фармасьютікалс, Інк. | Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату |
| JP2006522164A (ja) * | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のジアリール置換ピラゾール修飾因子 |
| WO2004089308A2 (en) | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| JP4110173B2 (ja) * | 2003-11-04 | 2008-07-02 | 高砂香料工業株式会社 | 白金錯体及び発光素子 |
| US20060173048A1 (en) | 2005-02-03 | 2006-08-03 | Mcarthur Silvia G | Imidazole derivatives |
| RU2451673C2 (ru) | 2006-03-29 | 2012-05-27 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРИДИНА И ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2 |
| US20070236568A1 (en) | 2006-04-11 | 2007-10-11 | Metke Anthony R | Method and system for communicating incident scene information |
-
2008
- 2008-03-24 US US12/053,648 patent/US8012986B2/en not_active Expired - Fee Related
- 2008-03-25 KR KR1020097020481A patent/KR101143152B1/ko not_active IP Right Cessation
- 2008-03-25 WO PCT/EP2008/053460 patent/WO2008119689A1/en active Application Filing
- 2008-03-25 AU AU2008233956A patent/AU2008233956B2/en not_active Ceased
- 2008-03-25 EP EP08718155A patent/EP2142527B1/en not_active Not-in-force
- 2008-03-25 MX MX2009010505A patent/MX2009010505A/es active IP Right Grant
- 2008-03-25 CA CA002681733A patent/CA2681733A1/en not_active Abandoned
- 2008-03-25 BR BRPI0809971-5A2A patent/BRPI0809971A2/pt not_active IP Right Cessation
- 2008-03-25 JP JP2010501476A patent/JP5303544B2/ja not_active Expired - Fee Related
- 2008-03-25 DE DE602008004236T patent/DE602008004236D1/de active Active
- 2008-03-25 CN CN2008800096420A patent/CN101641346B/zh not_active Expired - Fee Related
- 2008-03-25 AT AT08718155T patent/ATE493400T1/de active
- 2008-03-31 TW TW097111725A patent/TW200845999A/zh unknown
- 2008-03-31 AR ARP080101333A patent/AR065891A1/es unknown
- 2008-04-01 CL CL200800936A patent/CL2008000936A1/es unknown
- 2008-04-01 PE PE2008000591A patent/PE20090103A1/es not_active Application Discontinuation
-
2009
- 2009-09-07 IL IL200780A patent/IL200780A/en not_active IP Right Cessation
-
2011
- 2011-07-08 US US13/178,531 patent/US8415380B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010524852A (ja) | 2010-07-22 |
| KR20090117902A (ko) | 2009-11-13 |
| DE602008004236D1 (de) | 2011-02-10 |
| IL200780A0 (en) | 2010-05-17 |
| JP5303544B2 (ja) | 2013-10-02 |
| EP2142527A1 (en) | 2010-01-13 |
| US8012986B2 (en) | 2011-09-06 |
| EP2142527B1 (en) | 2010-12-29 |
| CN101641346B (zh) | 2013-11-06 |
| ATE493400T1 (de) | 2011-01-15 |
| BRPI0809971A2 (pt) | 2014-10-07 |
| CA2681733A1 (en) | 2008-10-09 |
| US8415380B2 (en) | 2013-04-09 |
| MX2009010505A (es) | 2009-10-19 |
| US20110263615A1 (en) | 2011-10-27 |
| IL200780A (en) | 2013-01-31 |
| TW200845999A (en) | 2008-12-01 |
| AR065891A1 (es) | 2009-07-08 |
| CL2008000936A1 (es) | 2008-10-03 |
| KR101143152B1 (ko) | 2012-05-08 |
| WO2008119689A1 (en) | 2008-10-09 |
| AU2008233956A1 (en) | 2008-10-09 |
| CN101641346A (zh) | 2010-02-03 |
| AU2008233956B2 (en) | 2013-05-02 |
| US20080280924A1 (en) | 2008-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090103A1 (es) | DERIVADOS DE PIRIDINA Y PIRIMIDINA COMO ANTAGONISTAS DEL mGluR2 | |
| KR102057366B1 (ko) | 치환된 벤젠 화합물 | |
| CN101426774B (zh) | 唑类甲酰胺衍生物 | |
| AU2021203497B2 (en) | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors | |
| JP4824567B2 (ja) | 新規化合物 | |
| PE20090775A1 (es) | Nuevos derivados de biarilo | |
| KR20210040368A (ko) | 사이클린 의존성 키나제의 억제제 | |
| PE20091379A1 (es) | Piridinil amidas para el tratamiento de transtornos del snc y metabolicos | |
| ES2623099T3 (es) | Compuestos de ácido dimetil-benzoico útiles para el tratamiento de afecciones inflamatorias | |
| PE20090437A1 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| PE20090893A1 (es) | Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5 | |
| AR058719A1 (es) | Derivados de isoxazol-4-il-oxadiazol | |
| PE20080150A1 (es) | Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) | |
| AR065794A1 (es) | Pirimidodiazepinas sustituidas | |
| PE20110793A1 (es) | Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona | |
| KR20150018788A (ko) | 혈전색전성 질환의 치료를 위한 인자 ｘｉａ 억제제로서 치환된 피롤리딘 | |
| HRP20100397T1 (hr) | INHIBITORI 11-ß-HIDROKSISTEROID-DEHIDROGENAZE 1 | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
| PE20081472A1 (es) | Compuestos de pirazolina | |
| EP1957476A1 (en) | L-alanine derivatives | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| KR101383538B1 (ko) | Ｎｋ3 수용체 길항제로서 피페리딘 유도체 | |
| HUE025031T2 (en) | Ethinyl derivatives as positive allosteric modulators of MGLUR5 | |
| PE20040828A1 (es) | Benzoxazinonas como modulares de 5-hidroxitriptamina (5-ht) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |